SPOTLIGHT: Analyst lengthens timeline for Cervarix
A Morgan Stanley analyst is raising the prospect that GlaxoSmithKline's Cervarix could be delayed five years beyond the 2009 approval expected by most analysts on Wall Street. Report
Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product
Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.
